Navigation Links
VIA Pharmaceuticals Expands Clinical Advisory Board With Leading Experts in Cardiovascular Disease
Date:11/12/2007

statements since they involve known and unknown risks, uncertainties and other factors which are, in some cases, beyond VIA's control and which could materially affect actual results, levels of activity, performance or achievements.

Factors that may cause actual results to differ materially from current expectations include, but are not limited to:

* our ability to obtain necessary financing;

* our ability to control our operating expenses;

* our ability to recruit and enroll patients for the CEA, ACS and FDG-

PET clinical trials;

* our ability to successfully complete our clinical trials of VIA-2291

on expected timetables and the outcomes of such clinical trials;

* the results of our clinical trials, including without limitation,

with respect to the safety and efficacy of VIA-2291;

* the outcome of any legal proceedings;

* our ability to obtain necessary FDA approvals;

* our ability to successfully commercialize VIA-2291;

* our ability to obtain and protect our intellectual property related

to our product candidates;

* our potential for future growth and the development of our product

pipeline;

* our ability to form and maintain collaborative relationships to

develop and commercialize our product candidates;

* general economic and business conditions; and

* the other risks described under the heading "Risk Factors" in our

Quarterly Report on Form 10-Q for the quarter ended June 30, 2007 on

file with the SEC and in Amendment No. 3 to our Registration

Statement on Form S-3, filed with the SEC October 15, 2007.

All forward-looking statements attributable to us or persons acting on our behalf are expressly qualified in their entirety by the cautionary statements set forth above. Forward-looking statements speak only as of
'/>"/>

SOURCE VIA Pharmaceuticals, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Vion Pharmaceuticals Pays Interest on 7.75% Convertible Senior Notes
2. China Biopharmaceuticals Holdings Announces Second Quarter 2007 Financial Results
3. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
4. XTL Biopharmaceuticals Announces Financial Results for the Six Months Ended June 30, 2007
5. Cadence Pharmaceuticals Reports Second Quarter 2007 Financial Results
6. Nabi Biopharmaceuticals to Present at Upcoming Industry Conferences
7. Anadys Pharmaceuticals Appoints Steve Worland, Ph.D. as President and Chief Executive Officer
8. Poniard Pharmaceuticals Announces Participation in Upcoming Conferences
9. NovaQuest Advances Virtual Development Model With Strategic Investment in TOPIGEN Pharmaceuticals
10. Drug Royalty Corporation (DRC) Announces Acquisition Regarding PEG-INTRON(R) From Enzon Pharmaceuticals, Inc. (ENZN)
11. Sunesis Pharmaceuticals Announces Reorganization to Focus Resources and Build Value in Clinical-Stage Programs
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/17/2014)... September 17, 2014 Beckman Coulter ... science and healthcare, has renewed its agreement with ... part of the agreement, Personify will continue to streamline ... emphasis on recruitment analytics, including time-to-fill, time-to-source and a ... our agreement with Personify was based on the success ...
(Date:9/17/2014)... The Pistoia Alliance, a global ... barriers to innovation in life sciences R&D through ... Nitsche as Executive Director Business Development North America, ... reach. , Carmen joins the Pistoia Alliance from ... At Accelrys, she managed various life sciences and ...
(Date:9/16/2014)... from jaw movements has been created by a group ... the device can generate electricity from eating, chewing and ... wearable electronic devices, such as hearing aids, cochlear implants, ... results of the device,s performance have been published today, ... and Structures . , Jaw movements have proved to ...
(Date:9/16/2014)... Rice University scientists who created a deicing film for ... as a transparent coating for glass. , The ... colleagues could keep glass surfaces from windshields to skyscrapers ... to radio frequencies (RF). , The technology was ... Applied Materials and Interfaces . , The ...
Breaking Biology Technology:Beckman Coulter Signs 3-year RPO Contract with Personify 2Beckman Coulter Signs 3-year RPO Contract with Personify 3Pistoia Alliance Expands Business Development with Appointment of Carmen Nitsche 2'Smart material' chin strap harvests energy from chewing 2Nanoribbon film keeps glass ice-free 2
... New, freely ... capture system , ... MA (PRWEB) May 10, 2010 -- Akaza Research announces the availability of the OpenClinica ... helps OpenClinica users find, share, and re-use clinical trial case report forms. It contains a ...
... GUANGZHOU, China , May 10 /PRNewswire-Asia/ -- China Medicine ... China of Western pharmaceuticals, traditional Chinese medicine,products, other nutraceuticals, medical devices, ... 9:00 a.m. Eastern,Time on Thursday, May 13, 2010 ... , , ...
... May 10 Fate Therapeutics, Inc. ... vice president of research and drug discovery.  Dr. Novak brings ... large pharmaceutical companies, including Roche and Wyeth, to apply transformative ... Novak will be responsible for Fate,s drug discovery and development ...
Cached Biology Technology:OpenClinica Case Report Form Library Now Available 2OpenClinica Case Report Form Library Now Available 3OpenClinica Case Report Form Library Now Available 4China Medicine Announces Conference Call to Discuss First Quarter 2010 Results 2Fate Therapeutics Appoints Tom Novak, Ph.D., as Vice President of Research and Drug Discovery 2Fate Therapeutics Appoints Tom Novak, Ph.D., as Vice President of Research and Drug Discovery 3
(Date:9/17/2014)... Campaigns against disposable plastic shopping bags and their environmental ... lawmakers passed the first statewide ban on the bags, ... But the plastic bag industry is not yielding without ... & Engineering News , the weekly newsmagazine of the ... with C&EN, reports that the anti-bag campaign logged its ...
(Date:9/17/2014)... Oncology-Bellvitge Biomedical Research Institute (ICO-IDIBELL), led by David ... normal accompanying cells in colorectal tumors. Analysis of ... tumors, predict the evolution of the patient and ... , Biomarkers , Colorectal cancer ... both sexes. About 30,000 new cases are diagnosed ...
(Date:9/17/2014)... [Brown University] After decades of decline, grasses have ... To the eye, the marsh in those places seems ... a key service of the marsh coastal protection ... but the ecosystem function hasn,t come back," said ecologist ... author of the study in the journal Biological ...
Breaking Biology News(10 mins):Five genes to predict colorectal cancer relapses 2Cape Cod saltmarsh recovery looks good, falls short 2Cape Cod saltmarsh recovery looks good, falls short 3
... Even moderate thyroid dysfunction during early pregnancy significantly increases ... universal screening in the first trimester, a new study ... Endocrine Society,s 94th Annual Meeting in Houston. "These ... studies that all pregnant women, irrespective of their risk ...
... Gallagher and his wife, Elizabeth, have made a $5 ... Family Professorships in Adult Stem Cell Research at the ... fund three new endowed professorships in adult and all ... Dame,s leadership in the field of stem cell research ...
... An elementary school science activity asks children who have each ... with string and tape to other "organisms" their assigned plant ... ecosystem web has been created, the teacher describes an event ... Other "organisms" that feel the tug then tug on their ...
Cached Biology News:Mild thyroid dysfunction in early pregnancy linked to serious complications 2Notre Dame establishes professorships in adult stem cell research 2Notre Dame establishes professorships in adult stem cell research 3Foundational concept of ecology tested by experiment 2Foundational concept of ecology tested by experiment 3Foundational concept of ecology tested by experiment 4
The Light Diagnostics Calicivirus Genotype 1&2 Typing OligoDetect assay is applicable for the qualitative detection of calicivirus RNA generated by an in-house validated in vitro nucleic acid amplifi...
X-Gal...
Recombinant Rat CINC-2 alpha, CF...
RABBIT ANTI SRC-RSV...
Biology Products: